Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Scopolamine dose-response trial in major depressive disorder
ACTRN12619000569101Phase 3Completed
- Sponsor
- The University of Auckland
- Start
- Aug 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of scopolamine in major depressive disorder (MDD) (4 arms), sponsored by The University of Auckland. Primary endpoint: Montgomery-Asberg Depression Rating Scale total score. Started Aug 2019; status: completed.
02
Drugs
scopolamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12619000569101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000569101.